Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders
Authors:
- 25 January 2005
- journal article
- clinical trial
- Published by Springer Nature in Psychopharmacology
- Vol. 179 (3) , 629-636
Abstract
Function in society can be severely affected by disruptive behaviors in adults. To examine the efficacy and safety of risperidone in the treatment of disruptive behavior disorders in intellectually disabled adults. Intellectually disabled patients with disruptive behavior disorder were randomly assigned to receive risperidone (n = 39) in a flexible dosage ranging from 1 to 4 mg/day (mean dosage, 1.45+/-0.08 mg/day) or placebo (n = 38) for 4 weeks of double-blind treatment. Efficacy at endpoint was measured primarily by using the Aberrant Behavior Checklist (ABC); secondary efficacy measures included the Behavior Problems Inventory and Clinical Global Impressions scales. After this 4-week period, patients could enter open-label treatment with risperidone for 48 weeks. Risperidone was well tolerated, and patients treated with risperidone demonstrated significantly greater improvement at endpoint on the ABC than those who received placebo [-27.3 points (52.8% improvement) versus -14.9 points (31.3% improvement); P = 0.036] and also improved on Behavior Problems Inventory and Clinical Global Impressions ratings. Over the 48-week, open-label follow-up period, there was a further decrease of 6.3 points (P < or = 0.05) on the ABC for patients who initially received risperidone and a decrease of 11.3 points (P < or = 0.05) for patients who initially received placebo and were switched to open-label risperidone. These results were achieved with a mean modal dosage of 1.8 mg/day. Risperidone is efficacious and well tolerated in managing disruptive behavior disorders in adults with intellectual disability.Keywords
This publication has 28 references indexed in Scilit:
- Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage IntelligenceAmerican Journal of Psychiatry, 2002
- A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with SchizophreniaNew England Journal of Medicine, 2002
- Risperidone in the Treatment of Behavioral Disturbances in Children and Adolescents with Borderline Intellectual Functioning: A Double-Blind, Placebo-Controlled Pilot TrialJournal of Child and Adolescent Psychopharmacology, 2001
- Effects of Risperidone on Aberrant Behavior of Persons With Developmental Disabilities: I. A Double-Blind Crossover Study Using Multiple MeasuresAmerican Journal on Mental Retardation, 2001
- A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2000
- Open-Label Treatment with Risperidone of 26 Psychiatrically-Hospitalized Children and Adolescents with Mixed Diagnoses and Aggressive BehaviorJournal of Child and Adolescent Psychopharmacology, 2000
- Early Conduct Problems and Later Life OpportunitiesJournal of Child Psychology and Psychiatry, 1998
- An Open Trial of Risperidone in Young Autistic ChildrenJournal of the American Academy of Child & Adolescent Psychiatry, 1998
- Risperidone in Adults with Autism or Pervasive Developmental DisorderJournal of Child and Adolescent Psychopharmacology, 1995
- Risperidone as add‐on therapy in behavioural disturbances in mental retardation: a double‐blind placebo‐controlled cross‐over studyActa Psychiatrica Scandinavica, 1993